BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,063 filers reported holding BAXTER INTL INC in Q3 2018. The put-call ratio across all filers is 0.66 and the average weighting 0.3%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $676,000 | -4.7% | 8,387 | +2.0% | 0.09% | -13.0% |
| Q2 2020 | $709,000 | +9.9% | 8,219 | +3.8% | 0.11% | -12.2% |
| Q1 2020 | $645,000 | -6.1% | 7,919 | -3.7% | 0.12% | +25.5% |
| Q4 2019 | $687,000 | -2.8% | 8,225 | +1.7% | 0.10% | -13.3% |
| Q3 2019 | $707,000 | +4.1% | 8,087 | -2.4% | 0.11% | +2.7% |
| Q2 2019 | $679,000 | -2.7% | 8,284 | -3.3% | 0.11% | -0.9% |
| Q1 2019 | $698,000 | +4.3% | 8,567 | -15.6% | 0.11% | -7.5% |
| Q4 2018 | $669,000 | -31.0% | 10,155 | -19.3% | 0.12% | -27.3% |
| Q3 2018 | $969,000 | +23.0% | 12,581 | -29.1% | 0.16% | +5.8% |
| Q4 2016 | $788,000 | -19.3% | 17,754 | -13.4% | 0.16% | -23.2% |
| Q3 2016 | $976,000 | -49.7% | 20,507 | -52.1% | 0.20% | -51.7% |
| Q2 2016 | $1,940,000 | +9.8% | 42,800 | -0.6% | 0.42% | +2.9% |
| Q1 2016 | $1,767,000 | +26.8% | 43,072 | +17.7% | 0.41% | +25.2% |
| Q4 2015 | $1,394,000 | +25.5% | 36,605 | +8.1% | 0.33% | +21.6% |
| Q3 2015 | $1,111,000 | -34.5% | 33,877 | +39.5% | 0.27% | -32.0% |
| Q2 2015 | $1,696,000 | -17.7% | 24,284 | -19.5% | 0.39% | -16.9% |
| Q1 2015 | $2,062,000 | -17.7% | 30,165 | -11.8% | 0.47% | -23.5% |
| Q4 2014 | $2,506,000 | +3.8% | 34,198 | +1.6% | 0.62% | +1.3% |
| Q3 2014 | $2,415,000 | – | 33,666 | – | 0.61% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Point | 41,000,000 | $2,482,140,000 | 22.00% |
| THUNDERBIRD PARTNERS LLP | 1,711,643 | $103,623,000 | 12.17% |
| SECTOR GAMMA AS | 1,070,333 | $64,798,000 | 9.42% |
| Veritas Asset Management LLP | 10,179,102 | $616,243,000 | 4.81% |
| 13D Management LLC | 194,807 | $11,794,000 | 4.18% |
| Progressive Investment Management Corp | 78,316 | $4,741,000 | 3.69% |
| Aristotle Capital Management, LLC | 6,846,307 | $414,476,000 | 3.46% |
| ARGENT CAPITAL MANAGEMENT LLC | 1,394,075 | $84,397,000 | 3.37% |
| Lipe & Dalton | 80,073 | $4,848,000 | 3.14% |
| PURA VIDA INVESTMENTS, LLC | 125,000 | $7,568,000 | 3.00% |